Next generation pneumococcal vaccines
Highlights
► Currently licensed pneumococcal vaccines are effective but also have limitations for worldwide use. ► There is much interest in the development of novel, broad pneumococcal vaccines. ► Antibodies or effector T cells directed against conserved pneumococcal proteins are protective. ► Three novel vaccine approaches: modified conjugates, protein-based, or an inactivated whole cell vaccine.
Introduction
Streptococcus pneumoniae causes approximately 11% of mortality worldwide in children under five [1•]. Pneumococcus causes invasive disease including sepsis, meningitis, and, most frequently, pneumonia; it is also a common cause of primarily mucosal diseases, such as acute otitis media (AOM) and sinusitis. Since the introduction of conjugated polysaccharide vaccines (PCVs) over 10 years ago, countries that have implemented universal vaccination programs have seen significant reductions in rates of pediatric invasive pneumococcal disease (IPD) due to strains covered by these vaccines [2]. While the success of PCVs has been substantial, their high manufacturing complexity and costs limit their use in developing nations where morbidity and mortality from pneumococcal disease are highest. Additionally, there are over 90 identified pneumococcal serotypes and the regional distribution of predominant serotypes varies. Therefore, an affordable vaccine that confers broad, preferably serotype-independent protection from pneumococcal disease remains a major global health priority.
Section snippets
Current vaccines
The longest standing pneumococcal vaccine currently available is Pneumovax®23 (Merck), composed of purified polysaccharides of 23 different serotypes. Pneumovax®23 is recommended for adults over the age of 65 and some high-risk patient populations, but its use in children is limited as polysaccharides are poorly immunogenic in infants and children under the age of two years. For the purposes of this review, further discussion of currently available vaccines will focus on PCVs.
A 7-valent PCV
Immunity to pneumococcal disease and colonization
Anticapsular antibodies are sufficient to prevent invasive disease such as meningitis and sepsis. Measurements of serotype-specific antibody titers and, more recently, opsonophagocytic activities (OPA) against various serotypes have been the mainstay of assessing immunogenicity of PCV preparations. What is less clear, however, is whether these antibodies are necessary for protection against invasive disease or whether these represent the natural mechanism whereby unimmunized children become
Mouse models of pneumococcal colonization and disease
It is important to remember that, with the exception of great apes, the only natural host of pneumococcus is the human. Thus, despite the wide use of mouse models in the scientific literature, some caution should be used when interpreting the results obtained from these studies, as they may not necessarily apply to the human. Mice are readily colonized by pneumococci of multiple types [10]; in some mice using specific pneumococcal strains, colonization can be shown to last several weeks, which
Novel vaccine approaches
For the purposes of this review, we will distinguish three vaccine approaches that are being considered.
Whole cell pneumococcal vaccines
Over a decade ago, our group began investigating the possibility of using a killed whole cell pneumococcal vaccine, where a large number of pneumococcal antigens would be presented at once. Such an approach is not novel, since published reports of numerous trials using this strategy date back as early as 1911. Accurately determining the efficacy of this approach in preventing pneumococcal infections or complications after influenza is difficult but a recent meta-analysis of this topic has
Conclusions
The advent and initial success of conjugate pneumococcal vaccines in 2000 brought about the hopes of reducing, if not virtually eliminating, pneumococcus as a major scourge of humanity. Since then, we have learned much about the ability of anticapsular antibodies to significantly reduce the burden of pneumococcal diseases both directly and indirectly, via the establishment of herd immunity. At the same time, we have also been reminded of the abilities of pneumococcus to adapt and overcome
Conflict of interest statement
RM is a member of the scientific advisory board of Genocea Biosciences, Cambridge MA and has served as a consultant for GSK Biologicals.
References and recommended reading
Papers of particular interest, published within the period of review, have been highlighted as:
• of special interest
•• of outstanding interest
Acknowledgements
The authors gratefully acknowledge past and present support from PATH, the Meningitis Research Foundation, the Pamela and Jack Egan Fund and the U.S. Public Health Service (grants AI067737 and AI066013).
References (48)
- et al.
Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates
Lancet
(2009) - Boslego J: Pneumococcal Vaccines: Progress and Challenges. In Phacilitate's 9th Annual North American Vaccine Forum...
- et al.
New technologies in using recombinant attenuated Salmonella vaccine vectors
Crit Rev Immunol
(2010) - et al.
Comparison of a regulated delayed antigen synthesis system with in vivo-inducible promoters for antigen delivery by live attenuated Salmonella vaccines
Infect Immun
(2011) - et al.
Comparative efficacy of autolysin and pneumolysin as immunogens protecting mice against infection by Streptococcus pneumoniae
Microb Pathog
(1992) - et al.
Protection of mice against fatal pneumococcal challenge by immunization with pneumococcal surface adhesin A (PsaA)
Microb Pathog
(1996) - et al.
CD4(+) T lymphocytes mediated protection against invasive pneumococcal infection induced by mucosal immunization with ClpP and CbpA
Vaccine
(2009) - et al.
PppA, a surface-exposed protein of Streptococcus pneumoniae, elicits cross-reactive antibodies that reduce colonization in a murine intranasal immunization and challenge model
Infect Immun
(2005) - et al.
Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine
J Infect Dis
(2010) - et al.
Invasive pneumococcal disease among infants before and after introduction of pneumococcal conjugate vaccine
JAMA
(2006)
Invasive pneumococcal disease caused by nonvaccine serotypes among alaska native children with high levels of 7-valent pneumococcal conjugate vaccine coverage
JAMA
Effect of pneumococcal conjugate vaccine on pneumococcal meningitis
N Engl J Med
Vaccination against colonizing bacteria with multiple serotypes
Proc Natl Acad Sci U S A
Age-specific incidence of invasive pneumococcal disease by serotype: are anticapsular antibodies the primary mechanism of protection against invasive disease?
PLOS Med
CD4+ T cells mediate antibody-independent acquired immunity to pneumococcal colonization
Proc Natl Acad Sci U S A
Interleukin-17A mediates acquired immunity to pneumococcal colonization
PLoS Pathog
Establishment of a Streptococcus pneumoniae nasopharyngeal colonization model in adult mice
Microb Pathog
Age- and serogroup-related differences in observed durations of nasopharyngeal carriage of penicillin-resistant pneumococci
J Clin Microbiol
Role of tumor necrosis factor alpha in pathogenesis of pneumococcal pneumonia in mice
Infect Immun
Role of pneumococcal surface protein C in nasopharyngeal carriage and pneumonia and its ability to elicit protection against carriage of Streptococcus pneumoniae
Infect Immun
Use of a whole genome approach to identify vaccine molecules affording protection against Streptococcus pneumoniae infection
Infect Immun
Identification and characterization of a novel family of pneumococcal proteins that are protective against sepsis
Infect Immun
Combined protective effects of anti-PhtD and anti-pneumococcal polysaccharides
Vaccine
Discovery of a novel class of highly conserved vaccine antigens using genomic scale antigenic fingerprinting of pneumococcus with human antibodies
J Exp Med
Cited by (97)
Expression, purification, and characterization of pneumococcal PsaA-PspA fusion protein
2021, Protein Expression and PurificationMucosal vaccines for streptococcus pneumoniae
2019, Mucosal Vaccines: Innovation for Preventing Infectious DiseasesEfficacy of whole-cell pneumococcal vaccine in mice: A systematic review and meta-analysis
2018, Microbial PathogenesisNovel polysaccharide-protein conjugates provide an immunogenic 13-valent pneumococcal conjugate vaccine for S. pneumoniae
2017, Synthetic and Systems Biotechnology